For severe or acute malaria see the statewide
Malaria Clinical Practice Guideline
Background
Malaria is caused by infection with protozoan parasites of the genus Plasmodium, transmitted by female mosquitos of the genus Anopheles. Four species cause nearly all infections in humans; P. falciparum, P. vivax, P. ovale and P. malariae. The microbiological and clinical features
vary between species (
Table 1). The prevalence of malaria in African refugees arriving in Australia was between 5-15%1-3 and as high as 25% in children from sub-Saharan Africa3 in the mid 2000s. This reduced with the introduction of pre-departure screening in 2005 (known as the Departure Health Check (DHC) since 2012). This is a voluntary health check for refugee entrants 3-7 days prior to departure for Australia. The DHC includes a rapid
diagnostic test (RDT) for malaria and treatment if positive,4 however screening is voluntary, and uptake is incomplete. Recent arrivals from Afghanistan have not had a DHC.
2016 ASID guidelines recommend malaria screening in people travelling from/through endemic areas (Bangladesh, Bhutan, Burma, India, Pakistan, Sri Lanka, African source countries. Note: not Egypt, Middle East). In 2017-2018, clinicians noted presentations of African children with P. falciparum malaria in South Australia and Victoria. We have seen cases of P. vivax in arrivals from Afghanistan.
- People living in endemic
areas develop anti-disease immunity followed by anti-parasite
immunity. They may have asymptomatic infection, however they are at
increased risk of symptomatic infection after migration as immunity
wanes.
- The highest burden of
disease occurs in young children (<5 years) prior to the
development of adequate immunity. This age group is at increased
risk of rapid deterioration and death.
- Severe
malaria <is signs of vital organ dysfunction (including hypoglycaemia) or
hyperparasitaemia (see below). Australian guidelines use a
cut-off of parasitaemia >2%. In general, only P. falciparum causes severe disease.
- Cerebral
malaria <is defined as a patient
with P. falciparum parasitaemia who does not respond to a
painful stimulus and has no other identified cause of
encephalopathy.5
- 98% of symptomatic
P. falciparum infections present within 3 months post
arrival.6
- 57% of symptomatic non
falciparum infection present within 3 months post arrival and 96%
within 12 months.6
- Infections can occur with
multiple species, which will affect treatment.
- Hypnozoites (dormant
liver forms) only occur in P. vivax and P. ovale.
These may cause a relapse of disease and require specific
treatment.
Assessment
History
- Countries of origin and transit, time since arrival
- Previous malaria
history and type if known
- Recent screening and/or
treatment (including prophylaxis)
- Current symptoms,
including fever pattern (a classic fever paroxysm consists of 3 stages (in order) cold, hot, sweat, lasting 6-10 hours total, usually late in the day). Symptoms of malaria may be non-specific, such as fever, cough, headache, abdominal pain or vomiting
- Capacity to access health
care in Australia (language skills, time since arrival, independent
transport)
- Others in family (who
will also need screening).
Exam
- Assess conscious state, signs of respiratory distress, shock, neurological symptoms
- Other findings on examination may include pallor (due to anaemia), bruising (from thrombocytopenia) or jaundice. Splenomegaly is found in
25-40% of symptomatic cases.
Screening
- Malaria should be
excluded as a priority in all febrile recently arrived refugees
from endemic areas (<3 months in Australia) with thick/thin
film(s) and a RDT. Malaria may still be the cause of a febrile
presentation in refugees settled for a longer period
- All children aged <5 years
from endemic areas, who have been in Australia <3 months should have malaria
screening (thick/thin film and rapid diagnostic test) if not
already performed, regardless of pre-departure screening/treatment OR the reason for
presentation
- All refugees from endemic
areas in Australia <3 months should be screened for malaria as
part of their outpatient assessment
- Refugees in Australia for
longer than 3 months warrant screening if there is a history of
recurrent febrile illnesses or a history of non-falciparum
malaria.
Investigations
Note: specify
countries of origin and transit and recent treatment on pathology
request forms.
Thick and thin
films
- If the initial film is
negative in patients suspected of having malaria, films should be
repeated at 12-24 hour intervals. A fingerprick is adequate.
Parasite counts are highest 4 hours after the fever has
peaked
- May not be sensitive if
parasite counts are low (<20-50/mcl, possibly <100/mcl)
- Are never reported as
negative, only as no parasites identified
- Thick films are used for diagnosis on malaria and parasite counts, thin films for morphology (species and stage)
- P. knowlesi is indistinguishable from P. malariae on microscopy - P. malariae cases with a history of travel to South East Asia are treated as P. knowlesi - hence is it essential to document countries of origin/transit.
Rapid diagnostic tests
- Test sensitivity of the
local RDT (ICT) is 84-97% (>90% for P. falciparum if
parasite count >100/mcl) and specificity is
81-100%
- The locally used RDT
gives information on the presence of Plasmodium spp (by
detecting parasite LDH) and whether the species is P. falciparum (by detecting HRPII)
- RDT may remain positive
for up to 4 weeks after successful parasite treatment (which is important to consider if people have been treated prior to arrival).
Other tests in symptomatic
patients
- FBE and film, platelet count, reticulocyte count
- VBG,
lactate, BSL
- UEC and LFT
- Coagulation
- G6PD screen if
quinine/primaquine will be used
- Screen for pregnancy if
indicated
- Consider group and hold if transfusion may be required.
Management
- All patients with malaria
should be managed in conjunction with an Infectious Diseases
Specialist
- All patients with malaria
require assessment in hospital. If there is any suggestion of
symptoms (i.e. in a patient who has had outpatient refugee
screening) the patient should be recalled to hospital
immediately
- All patients will require
a period of observation in hospital while treatment is commenced
and/or admission
- Patients with severe
malaria should be managed as for any severely unwell patient,
including checking BSL and monitoring for anaemia and for seizure
activity. Cardiac monitoring will be required for some medications
(i.e. intravenous quinine)
- Family members should
also be screened
- Malaria is a
notifiable disease.
Therapeutic guidelines for malaria are available (see RCH library drug information - intranet access required).
Additional considerations include:
- Artemether-lumefantrine (Riamet) is PBS listed (to weight 5kg/age 3 months) for malaria (therefore health care card rates). Dosing/timing need clear explanation - and picture-based dosing aids may be useful.
- Atovaquone-proguanil (Malarone) is a private script, and outpatient prescribing is usually not feasible because of cost
considerations.
- Chloroquine resistant
Pl vivax occurs in Timor, Papua New Guinea and the
Pacific region; other first line treatment options may be
needed.
- G6PD screening must be
performed prior to prescribing primaquine.
Outpatient management
Outpatient management may
be considered if all the following criteria are met (adapted from7)
- Age >5
years
- Clinically
well
- (Not pregnant)
- Reviewed by a senior
doctor and Infectious Diseases Unit consulted
- No clinical or laboratory
features of severe malaria
- Has resided in endemic
area for most of the previous year
- Tolerated first dose of
oral medication and observed 4-6 hours post
- Family has sufficient
understanding to ensure compliance and follow-up
- Family has sufficient
understanding and ability to return to hospital (by ambulance) if
child becomes more unwell
- Family have a discharge
letter stating child has malaria (including type of malaria), with
contact numbers and treatment details
- No other co-morbidity
requiring admission
Even if all criteria are
met, home-based nursing/Hospital in the Home should be considered for medication and
clinical supervision. There are additional considerations in
malaria-receptive areas in Northern Australia.
Follow-up
Patients should be seen in
Infectious Diseases outpatients at 28 days with repeat thick/thin
films and RDT, or immediately if symptoms recur.
Resources<
Severe malaria: WHO definition
[5]<
- Prostration
- Impaired
consciousness/coma
- Respiratory distress
(acidotic breathing)
- Multiple
convulsions
- Circulatory
shock
- Pulmonary oedema or Acute
Respiratory Distress Syndrome
- Abnormal
bleeding
- Jaundice
- Hemaglobinuria
- Severe
anaemia
- Hypoglycaemia (<2.2
mmol/L)
- Acidosis (HCO3 <15
mmol/L or base deficit >10 mmol/L)
- High lactate (>5
mmol/L)
- Hyperparasitaemia (>4% if non-immune
child in area unstable endemicity, > 20% in stable endemic
areas)
Table 1: Malaria species
Species |
P. falciparum |
P. vivax |
P. ovale |
P. malariae |
P. knowlesi
|
|
Predominant spp |
Sub Saharan Africa, PNG, Haiti |
South and North Asia, Eastern Europe, Central America parts South America
|
West Africa, occasional South East Asia, PNG |
Patchy worldwide, less common outside Africa |
Only SE Asia, especially Malaysia |
|
Equal prevalence: Oceania, East Asia, other parts South America |
Incubation |
7 - 14 days |
12 - 17 days |
15 - 18 days |
18 - 40 days |
8 - 12 days, up to 27 days |
Fever Paroxysm |
May be absent or subtertian |
Tertian (48 hours) |
Tertian (48 hours) |
Quartan (72 hours) |
Daily (24 hours) |
% Cells affected |
May be high |
< 2 - 3% |
< 2 - 3% |
< 1% |
May be high |
Cerebral malaria |
Yes |
No |
No |
No |
No |
Severe disease |
Yes |
Rare reports |
Rare reports |
No |
Yes |
Resistance reported |
Yes |
Yes |
No |
No |
No |
Natural history (without treatment) |
12 months |
3 years |
3 years |
Many years |
Variable, asymptomatic infections have been reported. |
Hypnozoite form (can relapse) |
No |
Yes |
Yes |
No |
No |
References
Immigrant health clinic resources. Author: Georgie Paxton, reviewed June 2020.